Fennec Pharmaceuticals Inc. FENC · Stock Open Fennec Pharmaceuticals Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Fennec Pharmaceuticals Inc. Analysis (FENC)
Is Fennec Pharmaceuticals Inc. a good investment? Fennec Pharmaceuticals Inc. (FENC) is currently trading at 10.72 USD. Market analysts have a consensus price target of 17.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Fennec Pharmaceuticals Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is 0.95.
Investor FAQ
Does Fennec Pharmaceuticals Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Fennec Pharmaceuticals Inc.?
Fennec Pharmaceuticals Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.12.
Company Profile
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 2, 2005 | 1:5 |
| Aug. 31, 2011 | 0.06 |
| Sept. 9, 2014 | 0.33 |
Community Discussion